Sign up to save your podcasts
Or
Share The Pillars of Launching a New Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Pillars of Launching a New Therapy
On today's episode of InsideOut, I'm joined by guest Diana Brainard, SVP and Virology Therapeutic Area Head at Gilead, to talk about the challenges and triumphs of launching a new therapy during the COVID-19 pandemic.
We dive into Remdesivir, an antiviral originally designed to target Ebola and later tested against a suite of lesser-known respiratory viruses. We discuss how Gilead moved the therapy into the clinic as quickly as possible to fight the COVID-19 pandemic. The outcome? It was one of only a few therapies granted emergency use authorization to treat severe COVID-19 patients in the pandemic’s earliest days.
View all episodes
By Mike Alkire, President of Premier, Inc.
5
1111 ratings
On today's episode of InsideOut, I'm joined by guest Diana Brainard, SVP and Virology Therapeutic Area Head at Gilead, to talk about the challenges and triumphs of launching a new therapy during the COVID-19 pandemic.
We dive into Remdesivir, an antiviral originally designed to target Ebola and later tested against a suite of lesser-known respiratory viruses. We discuss how Gilead moved the therapy into the clinic as quickly as possible to fight the COVID-19 pandemic. The outcome? It was one of only a few therapies granted emergency use authorization to treat severe COVID-19 patients in the pandemic’s earliest days.